Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN57,4557,490,35
Msft-0,51
Nokia4,764,79050,09
IBM0,81
Mercedes-Benz Group AG61,461,420,31
PFE-0,43
15.02.2025 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 14.02.2025
Biolife Solutions (NASDAQ Cons)
Závěr k 14.2.2025 Změna (%) Změna (USD) Objem obchodů (ks)
27,77 2,32 0,63 293 756
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 16.02.2025
Popis společnosti
Obecné informace
Název společnostiBioLife Solutions Inc
TickerBLFS
Kmenové akcie:Ordinary Shares
RICBLFS.O
ISIN-
Prioritní akciePreference Shares
Prioritní akciePreference Shares
Prioritní akciePreference Shares
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky30.09.2024
Počet zaměstnanců k 31.12.2023 409
Akcie v oběhu k 30.09.2024 46 227 940
MěnaUSD
Konstituent indexůS&P 600 Small Cap
Kontaktní informace
UliceSUITE 310, 3303 MONTE VILLA PARKWAY
MěstoBOTHELL
PSČ98021
ZeměUnited States
Kontatní osobaTroy Wichterman
Funkce kontaktní osobyChief Financial Officer
Telefon14 254 011 400
Fax14254021433
Kontatní telefon14 254 021 400

Business Summary: BioLife Solutions, Inc. is a supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
Financial Summary: BRIEF: For the nine months ended 30 September 2024, BioLife Solutions Inc revenues increased 4% to $85.7M. Net loss before extraordinary items decreased 57% to $13.1M. Revenues reflect Product Revenue-Cell processing segment increase of 4% to $53.2M, Service revenue-Storage and cold chain services segment increase of 13% to $13.7M. Lower net loss reflects Cost of product and rental r decrease from $8.3M (expense) to $0K.
Odvětvová klasifikace
TRBC2012Medical Equipment, Supplies & Distribution (NEC)
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYMedical Equipment & Supplies
MGSECTORHealthcare
NAICSSurgical and Medical Instrument Manufacturing
NAICSElectromedical and Electrotherapeutic Apparatus Manufacturing
NAICS2007Surgical & Medical Instrument Mfg
NAICS2007Electromedical Apparatus Mfg
NAICS1997Surgical and Medical Instrument Manufacturing
NAICS1997Electromedical and Electrotherapeutic Apparatus Manufacturing
SICElectromedical Equipment
SICSurgical And Medical Instruments
SICElectromedical Equipment



  • Poslední aktualizace: 16.02.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Chief Executive OfficerRoderick De Greef6319.10.202304.03.2016
Chief Financial OfficerTroy Wichterman3904.11.2021
Chief Human Resource OfficerSarah Aebersold49
Chief Scientific Officer, Executive Vice PresidentAby Mathew5202.12.2019
Senior Vice President - Global OperationsGeraint Phillips5804.01.202304.01.2023
Chief Marketing OfficerTodd Berard5502.12.2019
Chief Quality and Operations OfficerKaren Foster6413.04.2016
Chief Revenue OfficerGarrie Richardson5119.10.202319.10.2023